November 14-16, 2025 - The CAV First Annual Academic Conference & Expo (CAVAC) was successfully held in Xiamen, Fujian.

On October 23, 2025, Dr. Zhiming (Tiffany) Jiang, General Manager of Wantai Group, and Dr. Huirong (Harry) Pan, General Manager of Xiamen Innovax Biotech Co., Ltd. (“Innovax”), participated in the 37th International Papillomavirus Society (IPVS) Conference in Bangkok, Thailand. They chaired a dedicated symposium titled “A New Era of HPV Vaccines: The Efforts from Developing Country Manufacturers for Global Cervical Cancer Elimination,” which sparked lively discussions among attending experts and scholars. Meanwhile, under the theme “Together Against HPV,” Innovax’s booth (#09) also attracted active engagement.

Xiamen Innovax Biotech Co., Ltd. (Innovax) today announced its participation in the 37th International Papillomavirus Conference (IPVS 2025), taking place from October 23 to 26, 2025, in Bangkok, Thailand. In addition to hosting Booth 9, Innovax will present in a symposium—for the first time to the global academic community—the 34-month Phase III clinical data for the world's second HPV 9-valent vaccine, Cecolin 9, along with its localization strategy and implementation in Thailand.

Data from a 10-year follow-up study confirm that the Escherichia coli-produced HPV-16/18 bivalent vaccine (Cecolin) elicits sustained antibody responses and confers durable protection against HPV 16/18 associated high-grade cervical, vulvar or vaginal lesions and persistent infections for a minimum of 10 years post-vaccination.

On September 9, 2025, Xiamen Innovax Biotech Co., Ltd. (Innovax), a leading biotech company in vaccine innovation, announced a major public health milestone with the administration of the first dose of its Cecolin® 9 (HPV 9-valent vaccine) at the Shitang Community Health Service Center in Haicang District, Xiamen. This landmark event marks the official launch of China’s first independently developed HPV 9-valent vaccine, offering a new layer of protection for females aged 9 to 45 against cervical cancer.

Data from the three-year follow-up study confirm that Cecolin 9, the E. coli-produced HPV 9-valent vaccine co-developed by Innovax and Xiamen University, maintains non-inferior type-specific plateau antibody levels compared to a marketed HPV 9-valent vaccine in Chinese women aged 18-26 years, supporting its potential for enduring protection against targeted HPV types.